These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36372245)

  • 41. [Enzymological Studies on the Mechanisms of Pathogenesis of Diabetic Complications].
    Tanimoto T
    Yakugaku Zasshi; 2018; 138(3):405-415. PubMed ID: 29503433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline.
    Julián MT; Alonso N; Lupón J; Gavidia-Bovadilla G; Ferrer E; de Antonio M; López-Ayerbe J; Domingo M; Santiago-Vacas E; Zamora E; Codina P; Moliner P; Núñez J; Santesmases J; Puig-Domingo M; Bayes-Genis A
    Cardiovasc Diabetol; 2020 Mar; 19(1):38. PubMed ID: 32293458
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aldose reductase, still a compelling target for diabetic neuropathy.
    Oates PJ
    Curr Drug Targets; 2008 Jan; 9(1):14-36. PubMed ID: 18220710
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
    Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
    Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current Role of Dapagliflozin in Clinical Practice.
    Zargar AH; Trailokya AA; Ghag S; Pawar R; Aiwale A; Zalke A
    J Assoc Physicians India; 2021 Sep; 69(9):11-12. PubMed ID: 34585897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
    Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
    Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In Search of Differential Inhibitors of Aldose Reductase.
    Balestri F; Moschini R; Mura U; Cappiello M; Del Corso A
    Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454074
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study.
    Carbone S; Billingsley HE; Canada JM; Bressi E; Rotelli B; Kadariya D; Dixon DL; Markley R; Trankle CR; Cooke R; Rao K; B Shah K; Medina de Chazal H; Chiabrando JG; Vecchié A; Dell M; L Mihalick V; Bogaev R; Hart L; Van Tassell BW; Arena R; Celi FS; Abbate A
    Diabetes Metab Res Rev; 2020 Nov; 36(8):e3335. PubMed ID: 32415802
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study.
    Núñez J; Palau P; Domínguez E; Mollar A; Núñez E; Ramón JM; Miñana G; Santas E; Fácila L; Górriz JL; Sanchis J; Bayés-Genís A
    Clin Cardiol; 2018 Apr; 41(4):476-480. PubMed ID: 29663436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications.
    Kumar M; Choudhary S; Singh PK; Silakari O
    Future Med Chem; 2020 Jul; 12(14):1327-1358. PubMed ID: 32602375
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.
    Metra M; Eichhorn E; Abraham WT; Linseman J; Böhm M; Corbalan R; DeMets D; De Marco T; Elkayam U; Gerber M; Komajda M; Liu P; Mareev V; Perrone SV; Poole-Wilson P; Roecker E; Stewart J; Swedberg K; Tendera M; Wiens B; Bristow MR;
    Eur Heart J; 2009 Dec; 30(24):3015-26. PubMed ID: 19700774
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration.
    Johnson BF; Nesto RW; Pfeifer MA; Slater WR; Vinik AI; Chyun DA; Law G; Wackers FJ; Young LH
    Diabetes Care; 2004 Feb; 27(2):448-54. PubMed ID: 14747227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.
    Deedwania PC; Giles TD; Klibaner M; Ghali JK; Herlitz J; Hildebrandt P; Kjekshus J; Spinar J; Vitovec J; Stanbrook H; Wikstrand J;
    Am Heart J; 2005 Jan; 149(1):159-67. PubMed ID: 15660048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipid peroxidation-derived aldehydes and oxidative stress in the failing heart: role of aldose reductase.
    Srivastava S; Chandrasekar B; Bhatnagar A; Prabhu SD
    Am J Physiol Heart Circ Physiol; 2002 Dec; 283(6):H2612-9. PubMed ID: 12388223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic analysis of aldose reductase in diabetic complications.
    Chung SS; Chung SK
    Curr Med Chem; 2003 Aug; 10(15):1375-87. PubMed ID: 12871135
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Kinetic and molecular docking studies of loganin and 7-O-galloyl-D-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase.
    Lee CM; Jung HA; Oh SH; Park CH; Tanaka T; Yokozawa T; Choi JS
    Arch Pharm Res; 2015 Jun; 38(6):1090-8. PubMed ID: 25315636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy.
    Kim AH; Jang JE; Han J
    Biomed Pharmacother; 2022 Jan; 145():112463. PubMed ID: 34839258
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical assessment of complementary treatment with Qishen Yiqi dripping pills on ischemic heart failure: study protocol for a randomized, double-blind, multicenter, placebo-controlled trial (CACT-IHF).
    Hou YZ; Wang S; Zhao ZQ; Wang XL; Li B; Soh SB; Mao JY
    Trials; 2013 May; 14():138. PubMed ID: 23672353
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options.
    Srivastava SK; Ramana KV; Bhatnagar A
    Endocr Rev; 2005 May; 26(3):380-92. PubMed ID: 15814847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discoveries in research on diabetic keratopathy.
    Cisarik-Fredenburg P
    Optometry; 2001 Nov; 72(11):691-704. PubMed ID: 12363257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.